Related Experiment Video
Updated: Dec 15, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Research progress on laboratory diagnosis of drug-induced liver injury]
1Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200025, China.
Abstract:
Drug-induced liver injury (DILI) is one of the common adverse drug reactions in the clinic and is also the main reason for the withdrawal of new drugs from the market. Although the overall incidence rate of DILI is not high; however, it can cause severe adverse outcome and even death, and has become the core cause of acute liver failure in Europe and the United States. In addition, DILI diagnosis is a puzzling problem for clinicians. Drug re-stimulation can be used as the "gold standard" in the diagnosis of DILI, but it may re-induce liver failure, so it cannot be recommended for clinical use. Currently, laboratory diagnostic methods including serum biomarker, genetic testing, scoring scale, and so on are available for DILI.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Therapeutic Drug Monitoring: Drug Analysis Methods
Drug Discovery: Overview

